Quince Therapeutics

Quince Therapeutics

Quince Therapeutics, formerly known as Erytech Pharma, emerged in 2020 after a merger and rebranding that consolidated assets around a lead A-T program. The company's wealth origin is undisclosed, but it operates as a Delaware-incorporated public entity with no single-family-office affiliation. The company's strategy centers on a single drug candidate, a small molecule known as EryDex (formerly Erytech's asparaginase platform), initially developed for A-T — a rare neurodegenerative disorder. As of 2024, the drug was in Phase 3 clinical trials (per the firm's SEC filings, 2024). Quince has not disclosed additional pipeline candidates or preclinical assets beyond this lead program. The geographic focus is primarily the United States, with some prior European operations linked to the pre-merger entity. Quince Therapeutics does not disclose AUM or deployment figures, as it is not an investment vehicle but a biotech company. Staffing levels and team composition are not public; the company does not operate family-office-style structures, philanthropic arms, or investment vehicles beyond its research and development mandate. The structural differentiator for Quince is its single-asset focus in a niche rare disease area, contrasting with larger biotechs or diversified family offices. No succession or governance details are publicly available beyond standard public-company disclosures.